Your browser doesn't support javascript.
loading
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese, Daniela; Daperno, Marco; Fiorino, Gionata; Savarino, Edoardo; Mosso, Elena; Biancone, Livia; Testa, Anna; Sarpi, Lucio; Cappello, Maria; Bodini, Giorgia; Caprioli, Flavio; Festa, Stefano; Laino, Gabriella; Maconi, Giovanni; Mazzuoli, Silvia; Mocci, Giammarco; Sartini, Alessandro; D'Amore, Alessandra; Alivernini, Stefano; Gremese, Elisa; Armuzzi, Alessandro.
Afiliação
  • Pugliese D; IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
  • Daperno M; Gastroenterology Unit, A.O. Ordine Mauriziano, Turin, Italy.
  • Fiorino G; IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Italy.
  • Savarino E; Gastroenterology Unit, Department Surgery, Oncology and Gastroenterology, University of Padua, Italy.
  • Mosso E; General and Specialistic Medicine/Gastroenterology, Città della Salute e della Scienza di Torino, Italy.
  • Biancone L; University of Rome Tor Vergata, Department of Systems Medicine, Gastroenterology, Rome, Italy.
  • Testa A; Federico II University, Gastroenterology, Naples, Italy.
  • Sarpi L; Gastroenterologia ed Endoscopia Digestiva Aziendale USL Umbria1, Perugia, Italy.
  • Cappello M; Gastroenterology and Hepatology Section, DiBiMis, University of Palermo, Palermo, Italy.
  • Bodini G; Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Caprioli F; Department of Pathophysiology and Transplantation, University of Milan and Gastroenterology and Endoscopy Unit, IRCCS Cà Granda, IRCCS Policlinico Hospital, Milan, Italy.
  • Festa S; IBD Unit, San Filippo Neri Hospital, Rome, Italy.
  • Laino G; Department of New Technologies and Translational Research in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Maconi G; Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy.
  • Mazzuoli S; Gastroenterology Unit, San Nicola Pellegrino Hospital, Trani, Italy.
  • Mocci G; Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.
  • Sartini A; Department of Internal Medicine, Gastroenterology Unit, University of Modena and Reggio Emilia, Modena, Italy.
  • D'Amore A; Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy.
  • Alivernini S; Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy.
  • Gremese E; Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy.
  • Armuzzi A; IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: alearmuzzi@yahoo.com.
Dig Liver Dis ; 51(7): 972-977, 2019 07.
Article em En | MEDLINE | ID: mdl-30992173
BACKGROUND: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. AIMS: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. METHODS: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. RESULTS: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. CONCLUSIONS: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Doenças Inflamatórias Intestinais / Artrite Psoriásica / Fármacos Dermatológicos / Ustekinumab Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Doenças Inflamatórias Intestinais / Artrite Psoriásica / Fármacos Dermatológicos / Ustekinumab Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article